CYTK241220P80000
- 22.45
- 0.000.00%
Cytokinetics Newsroom
RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)
Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
Cytokinetics' Hold Rating Amid Bayer Partnership and Acquisition Uncertainty
Cytokinetics Gains 'Buy' Rating Due to Strategic Collaborations and Potential FDA Approval
Cytokinetics Analyst Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Positive Clinical Outcomes Drive Buy Rating for Cytokinetics's Cardiac Myosin Modulators
Cytokinetics Analyst Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $80
Cytokinetics: Strategic Growth and Strong Financial Positioning Drive Buy Rating
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $72
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
Cytokinetics Initiated With an Outperform at RBC Capital
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Analyst Ratings
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $60 to $120
Cytokinetics Hold Rating: Balancing Progress and Challenges Amid Uncertain Upside